Generic Name: Cellcept

What is Cellcept?

Mycophenolate mofetil did not inhibit early events in the activation of human peripheral blood mononuclear cells, such as the production of interleukin-1 IL-1 and interleukin-2 IL-2but did block the coupling of these events to DNA synthesis and proliferation. Following oral and intravenous administration, mycophenolate mofetil undergoes rapid and complete metabolism to MPA, the active metabolite. Oral absorption of the drug is rapid and essentially complete. MPA is metabolized to form the phenolic glucuronide of MPA MPAG which is not pharmacologically active.

The area under the plasma-concentration time curve AUC for MPA appears to increase in a dose-proportional fashion in renal transplant patients receiving multiple doses of mycophenolate mofetil up to a daily dose of 3 g see Table 1.

Food 27 g fat, 650 calories had no effect on the extent of absorption MPA AUC of mycophenolate mofetil when administered at doses of 1. Mean blood to plasma ratio of radioactivity concentrations was approximately 0. At concentrations that exceeded what is encountered clinically, cyclosporine, digoxin, naproxen, prednisone, propranolol, tacrolimus, theophylline, tolbutamide, and warfarin did not increase the free fraction of MPA. Following oral and intravenous dosing, mycophenolate mofetil undergoes complete metabolism to MPA, the active metabolite.

Metabolism to MPA occurs presystemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to form the phenolic glucuronide of MPA MPAG which is not pharmacologically active.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. Neither Everyday Health nor its licensor assume any responsibility for any aspect of healthcare administered with the aid of the information provided. If you have any questions about the drugs you are taking, check with your doctor, nurse or pharmacist. If you would like to obtain more information about these advertising practices and to make choices about online behavioral advertising, please click here.

Advanced document searchThis is a summary of the European public assessment report EPAR. It explains how the Committee for Medicinal Products for Human Use CHMP assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet also part of the EPAR or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion also part of the EPAR.

CellCept is a medicine containing the active substance mycophenolate mofetil. CellCept is used to prevent the body from rejecting a transplanted kidney, heart or liver. It is used with ciclosporin and corticosteroids other medicines used to prevent organ rejection.

How should I take Cellcept?

CellCept Oral Suspension contains aspartame, a source of phenylalanine 0. Therefore, care should be taken if CellCept Oral Suspension is administered to patients with phenylketonuria. The highest dose tested was 0. The highest dose was 0. While these animal doses were lower than those given to patients, they were maximal in those species and were considered adequate to evaluate the potential for human risk see WARNINGS. The genotoxic potential of mycophenolate mofetil was determined in five assays.

What should I avoid while taking Cellcept?

Monitor patients receiving mycophenolate with highly protein bound drugs, such as phenytoin for changes in clinical status. Platelet Inhibitors: Platelet Inhibitors inhibit platelet aggregation and should be used cautiously in patients with thrombocytopenia, as mycophenolate can also cause thrombocytopenia. Polysaccharide-Iron Complex: Conflicting information has been reported regarding coadministration of mycophenolate and iron salts. Probenecid: Probenecid is a known inhibitor of renal tubular secretion, and the inactive metabolite, MPAG undergoes tubular secretion.

Increased MPAG concentrations can cause increased mycophenolic acid systemic exposure and thus, adverse effects. Patients receiving both drugs should be monitored carefully. Procarbazine: Concurrent use of procarbazine with other agents which cause bone marrow or immune suppression such as other antineoplastic agents or immunosuppressives may result in additive effects. Proton pump inhibitors: Concomitant administration of proton pump inhibitors PPIs with mycophenolate mofetil Cellcept appears to reduce MPA exposure AUC-12h 25.

Cellcept side effects

Neoplasms Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin see section 4. Infections Patients treated with immunosuppressants, including CellCept, are at increased risk for opportunistic infections bacterial, fungal, viral and protozoalfatal infections and sepsis see section 4.

Blood and immune system Patients receiving CellCept should be monitored for neutropenia, which may be related to CellCept itself, concomitant medications, viral infections, or some combination of these causes. Gastro-intestinal CellCept has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation. Interactions Caution should be exercised when switching combination therapy from regimens containing immunosuppressants, which interfere with MPA enterohepatic recirculation e.

Special populations Elderly patients may be at an increased risk of adverse events such as certain infections including cytomegalovirus tissue invasive disease and possibly gastrointestinal haemorrhage and pulmonary oedema, compared with younger individuals see section 4.

Common Cellcept ide effects may include:

  • Cellcept comes in tablet form, capsule of liquid form, and also as a powder that is mixed with Dextrose to make an IV drug.

  • Patients with diabetes mellitus may have greater difficulty with their blood glucose regulation while taking mycophenolate.

  • If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911.

  • Penicillamine: Agents such as immunosuppressives have adverse reactions similar to those of penicillamine.

I took the cellcept for 3 mo. I am convinced that I got it as a result of taking statin drugs, and there is an article from the Mylan sp.

School of Pharmacy at Duquesne University saying it can be triggered by heart meds, including statins. I think, after much research, that after years of muscle problems and being prescribed a different statin each time I would have adverse reactions and take myself off them, they caused DNA damage and that is why nothing works to cure mine.

Where can I get more information?

  • Hepatic disease with other etiologies, such as primary biliary cirrhosis, may show a different effect.

  • Call your healthcare provider right away.